Nomura India maintained its 'Neutral' rating with a target price of Rs 1,100. It cut its FY26 Ebitda estimates by 2 per cent ...

--Off 18.33% from its 52-week high of $82.03 hit Wednesday, Jan. 15, 2025 --Up 11.22% from its 52-week low of $60.23 hit Monday, May 5, 2025 --Down 6.45% from 52 weeks ago --Off 18.33% from its 2025 ...

Cellectis said it has enough cash to fund operations through 2024. The company presented positive research data this past week. Cellectis has several therapies in trials, but no marketed product yet.

The maker of shower toilets and bathroom ceramics said its third-quarter sales rose 5.3% to 794.1 million Swiss francs ($875.52 million), while operating profit rose 16.4% to 227.4 million francs.